Key Takeaways
- • Axena Health, a women's health company focused on pelvic health, was named a Best in Class winner in the Women's & Family Health category of the Digital Health Hub Foundation's 2026 Digital Health & AI Awards, per a Business Wire announcement.
- • Axena was one of 38 competitive winners selected from more than 1,300 participating companies worldwide, after multiple rounds of evaluation by hundreds of experts in healthcare, technology, clinical medicine, venture capital and innovation.
- • Winners were celebrated November 16 at HLTH USA in Las Vegas.
- • The recognition centers on Axena's flagship Leva Pelvic Health System, a prescription, FDA-cleared, medication-free device for urinary and chronic fecal incontinence used in five minutes a day at home.
- • CEO and Chief Medical Officer Samantha Pulliam, MD, FACOG, framed the award as validation that pelvic health belongs at the center of women's and family healthcare.
Summary
The Digital Health & AI Awards recognize companies and innovations shaping the future of healthcare. Axena was one of 38 winners chosen from more than 1,300 participating companies worldwide. Entrants went through multiple rounds of evaluation by hundreds of experts in healthcare, technology, clinical medicine, venture capital and innovation.
The award relates to Axena's flagship product, the Leva Pelvic Health System. The company describes Leva as a prescription-only, non-invasive, medication-free treatment for urinary incontinence and chronic fecal incontinence. The program brings supervised pelvic floor muscle training into women's homes in about five minutes a day. It combines a small FDA-cleared vaginal motion sensor with software that provides real-time visualization of pelvic movement, personalized coaching, progress tracking and clinician monitoring. The company states that multiple clinical trials and peer-reviewed publications support its efficacy, including two studies in Obstetrics and Gynecology, the journal of the American College of Obstetricians and Gynecologists.
Company leadership cited the scale of the underlying condition. Axena states that urinary and fecal incontinence are underreported, affecting more than 78 million and 12 million women in the U.S., respectively. Pulliam said in the release that many women are told incontinence is a normal part of childbearing or aging and never learn that effective, non-invasive treatment exists. The release is a company announcement; the award figures and details are as reported by Axena and Business Wire.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.